Sun Pharma Q1 Results Today: Sun Pharmaceutical Q1FY25 net profit came in at Rs 2,835.62 crore, up 40.2% from Rs 2,022.54 crore in Q1FY24. The company’s consolidated Q1FY25 revenue from operations came in at Rs 12,653 crore, up 6% from Rs 11,940.84 crore a year ago.

The Q1 performance was driven by strong sales in both domestic and US markets. The India formulation sales came in 16.4% higher while US formulation sales were stable at $466 million. Global specialty sales were up 14.7% and accounted for 17.7% of Q1 sales.

However, Sun Pharma’s Q1 margins came under pressure as R&D investments in Q1FY25 were higher at Rs 794 crore compared to Rs 679 crore in Q1FY24, up 16%.

Speaking on the Q1 results, Dilip Shanghvi, Chairman and Managing Director, Sun Pharma said, “Sun has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe and the completion of acquisition of Taro minority shares. These steps advance our innovative as well as generic business offerings, and will help us serve patients better.”

On June 24, 2024, the Group completed its acquisition of all outstanding ordinary shares of Taro Pharmaceutical other than shares already held for $347.7 million.

Also Read

Sun Pharma Q1FY25 Results – Highlights

-Q1 Gross Sales at Rs 12524.5 crore up 6.3% YoY

-Q1 Net Profit at Rs 2835.6 crore, adjusted growth of 20.9%.

-Gross sales at Rs 12524.5 crore, growth of 6.3%

-India Formulation sales at Rs 41,44.5 crore, up 16.4%

-US Formulation sales at US$ 466 million, lower by 1.0%

-Global Specialty sales at US$ 266 million, up 14.7%

-Global Specialty sales accounted for 17.7% of Q1FY25 sales

-Emerging Markets Formulation sales at US$ 284 million, up by 8.8%

-Rest of World Formulation sales at US$ 190 million, down by 2.9%

-R&D investments at Rs 794 crore compared to Rs 679.6 crore for Q1FY24

-EBITDA at Rs 3607.6 crore (including other operating revenues), up 8.3%. EBITDA margin for Q1 at 28.5% vs 27.9% during Q1FY24.

-Net profit for Q1FY25 at Rs 2835.6 crore, up 40.2% YoY; up 20.9% over adjusted net profit of Q1FY24.